Galapagos NV

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  

28 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces first half-year 2023 financial results

03 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

15 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

12 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

05 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

23 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

22 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

05 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces first quarter 2023 financial results

04 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer

02 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

26 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting

25 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos and NovAliX enter into an integrated drug discovery collaboration

30 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting

23 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces full year 2022 results and outlook for 2023

23 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

09 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

08 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

10 Jan 2023 15:01:00 By Nasdaq GlobeNewswire